lenalidomide has been researched along with Anemia in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (20.97) | 29.6817 |
| 2010's | 38 (61.29) | 24.3611 |
| 2020's | 11 (17.74) | 2.80 |
| Authors | Studies |
|---|---|
| Chudej, J; Guman, T; Hlebaskova, M; Kucerikova, M; Sokol, J; Stasko, J; Stecova, N; Valekova, L | 1 |
| Bazinet, A; Bravo, GM | 1 |
| Aul, C; Bock, O; Buesche, G; Ebert, BL; Ganser, A; Germing, U; Giagounidis, A; Göhring, G; Kreipe, H; Ribezzo, F; Schlegelberger, B; Schneider, RK; Teoman, H | 1 |
| Garcia-Manero, G; Komrokji, RS; Volpe, VO | 1 |
| Sallman, DA; Wang, C | 1 |
| Park, S | 1 |
| Bewersdorf, JP; Zeidan, AM | 1 |
| Greenberg, P; Hellström-Lindberg, E; Tobiasson, M | 1 |
| Al Ali, N; Castillo-Tokumori, F; Komrokji, R; Kuykendall, AT; Lancet, J; Padron, E; Sallman, D; Sweet, K; Talati, C; Yun, S | 1 |
| Ara, T; Fukuhara, O; Harigae, H; Ito, T; Katsuoka, Y; Kimura, T; Kobayashi, N; Minauchi, K; Nakajima, S; Noji, H; Onishi, Y; Ota, S; Sasaki, O; Yamamoto, J; Yokoyama, H | 1 |
| Carraway, HE; Saygin, C | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Casadebaig Bravo, ML; Drach, J; Fu, T; Goy, A; Habermann, TM; Kalayoglu Besisik, S; Luigi Zinzani, P; Ramchandren, R; Takeshita, K; Tuscano, JM; Witzig, TE; Zhang, L | 1 |
| Betancourt Cuellar, SL; Cabanillas, ME; Falchook, GS; Fanale, MA; Fu, S; Glitza, IC; Hong, DS; Janku, F; Naing, A; Sakamuri, D; Subbiah, V; Tsimberidou, AM; Wheler, JJ | 1 |
| Kiselev, P; Ma, X; Scott, BL; Steensma, DP; Sugrue, MM; Swern, AS | 1 |
| Burgos, S; Fuente, L; Garcia-Manero, G; Jabbour, EJ; Kanagal-Shamanna, R; Mela-Osorio, MJ; Montalban-Bravo, G; Soltysiak, KA | 1 |
| Al Ali, NH; Cogle, C; Komrokji, RS; Lancet, JE; Lis, AF; Padron, E; Sallman, D; Tinsley, S | 1 |
| Gattermann, N; Germing, U; Kaivers, J; Kobbe, G; Kündgen, A; Schroeder, T | 1 |
| Burgstaller, S; Fridrik, M; Gisslinger, H; Hojas, S; Kühr, T; Ludwig, H; Mayrbäurl, B; Pöhnl, R; Pötscher, M; Schlögl, E; Thaler, J; Zauner, D | 1 |
| Adès, L; Fenaux, P | 1 |
| Scott, LJ; Syed, YY | 1 |
| Caba-Molina, M; Claver-Ferré, C; García-Marcos, SA; Gómez-Morales, M; Martín-Gómez, MA; Palacios-Gómez, ME | 1 |
| Ardanaz, MT; Arrizabalaga, B; Azaceta, G; Bargay, J; Cabrero, M; Calabuig, M; Cedena, T; Cerveró, C; Collado, R; del Cañizo, C; Díez-Campelo, M; García, M; Luño, E; Morell, MJ; Muñoz, JA; Nomdedeu, B; Pedro, C; Rodríguez, MJ; Rojas, SM; Simiele, A; Xicoy, B | 1 |
| Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Terpos, E | 1 |
| Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G | 1 |
| Birgegård, G | 1 |
| Shibayama, H | 1 |
| Adam, Z; Autzinger, EM; Greil, R; Heintel, D; Kasparu, H; Kuehr, T; Ludwig, H; Müldür, E; Poenisch, W; Rauch, E; Weißmann, A; Zojer, N | 1 |
| Sofronescu, AG; Wedel, W | 1 |
| Arnulf, B; Bakala, J; Banos, A; Bories, C; Brice, P; Choquet, S; Demarquette, H; Dib, M; Fouquet, G; Guidez, S; Herbaux, C; Karlin, L; Leblond, V; LeGouill, S; Leleu, X; Louni, C; Martin, A; Morel, P; Nudel, M; Ohyba, B; Petillon, MO; Poulain, S; Salles, G; Thielemans, B; Tournilhac, O | 1 |
| Banos, A; Benramdane, R; Beyne-Rauzy, O; Bordessoule, D; Bouabdallah, K; Caillot, D; Chevret, S; Cheze, S; Chouffi, B; Cony-Makhoul, P; De Renzis, B; Delaunay, J; Dreyfus, F; Fenaux, P; Fontenay, M; Gardin, C; Gruson, B; Guerci-Bresler, A; Guilhot, F; Gyan, E; Isnard, F; Kosmider, O; Laribi, K; Legros, L; Lejeune, J; Maloum, K; Nimuboma, S; Petit, R; Preudhomme, C; Renneville, A; Rose, C; Salanoubat, C; Sanhes, L; Sardnal, V; Slama, B; Soussain, C; Stamatoullas, A; Taksin, AL; Tertian, G; Toma, A; Wattel, E; Wickenhauser, S | 1 |
| Bouchnita, A; Eymard, N; Koury, MJ; Moyo, TK; Volpert, V | 1 |
| Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S | 1 |
| Elkon, J; Haroun, F; Mener, A; Tabbara, I | 1 |
| Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS | 1 |
| Al Ali, N; Cluzeau, T; Fenaux, P; Gore, SD; Komrokji, R; Park, S; Prebet, T; Sekeres, MA; Sugrue, MM; Toma, A; Vey, N | 1 |
| Stahl, M; Zeidan, AM | 1 |
| Cosler, LE; Ferro, SA; Greenberg, PL; Lyman, GH | 1 |
| Anderson, KC; Baron, AD; Branagan, AR; Chu, L; Hunter, ZR; Hyman, PM; Ioakimidis, L; Kash, JJ; Munshi, NC; Musto, P; Nawfel, EL; Nunnink, JC; Patterson, CJ; Sharon, DJ; Soumerai, JD; Terjanian, TO; Treon, SP | 1 |
| Harada, H; Kimura, A; Matsuda, A; Ozawa, K; Suzuki, K; Suzuki, T; Takatoku, M; Takeshita, K; Taniwaki, M; Tohyama, K; Tsudo, M; Watanabe, M; Yanagita, S; Yoshida, Y | 1 |
| Bueso-Ramos, C; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; Manshouri, T; Quintás-Cardama, A; Ravandi, F; Thomas, D; Verstovsek, S | 1 |
| Bekele, NB; Carter, CM; Mathew, P; Pagliaro, L; Tannir, N; Tu, SM | 1 |
| Komrokji, RS; List, AF | 1 |
| Baz, R; Chanan-Khan, AA; Finley-Oliver, E; Hussein, MA; Lebovic, D; Lee, K; Miller, KC; Patel, M; Sher, T; Wood, M | 1 |
| Komrokji, RS; Lancet, JE; List, AF | 1 |
| Lachs, MS; Ritchie, EK | 1 |
| Bryan, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H; Prescott, H | 1 |
| Bardet, V; Dreyfus, F; Park, S; Vassilieff, D; Viguié, F | 1 |
| Biemond, BJ | 1 |
| Anderson, K; Laubach, J; Richardson, P | 1 |
| González Rodríguez, AP | 1 |
| Alimena, G; Breccia, M; Cannella, L; Carmosino, I; Cuzzola, M; Ferretti, A; Girmenia, C; Latagliata, R; Loglisci, G; Oliva, EN; Santopietro, M; Volpicelli, P; Vozella, F | 1 |
| Ahmed, A; Al-Zoubi, A; Anderson, T; Couriel, D; Detweiler-Short, K; Durecki, DE; Dytfeld, D; Griffith, KA; Jagannath, S; Jakubowiak, AJ; Jobkar, T; Kaminski, M; Lebovic, D; McDonnell, K; Mietzel, M; Nordgren, B; Stockerl-Goldstein, K; Vesole, DH; Vij, R | 1 |
| Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S | 1 |
| Allred, JB; Byrne, C; Cortes, J; Giles, F; Hogan, WJ; Jones, D; Kantarjian, HM; Ketterling, RP; Lasho, TL; Litzow, MR; McClure, RF; Mesa, RA; Tefferi, A; Thomas, D; Verstovsek, S; Zeldis, JB | 1 |
| List, AF | 2 |
| Baker, AF; Bellamy, W; Green, S; List, AF | 1 |
| Kurtin, S; Sokol, L | 1 |
| Ozawa, K | 1 |
| Ohyashiki, K | 1 |
22 review(s) available for lenalidomide and Anemia
| Article | Year |
|---|---|
New Approaches to Myelodysplastic Syndrome Treatment.
Topics: Anemia; Antineoplastic Agents; Azacitidine; Humans; Lenalidomide; Myelodysplastic Syndromes; Quality of Life | 2022 |
SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes.
Topics: Anemia; Humans; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Risk Factors | 2023 |
Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes.
Topics: Anemia; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life | 2023 |
[Treatment of lower risk myelodysplastic syndromes].
Topics: Anemia; Hematinics; Humans; Lenalidomide; Myelodysplastic Syndromes; Risk; Thrombocytopenia | 2023 |
Evolving therapies for lower-risk myelodysplastic syndromes.
Topics: Anemia; Blood Transfusion; Chelation Therapy; Clinical Trials as Topic; Cri-du-Chat Syndrome; Drugs, Investigational; Forecasting; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Iron Overload; Lenalidomide; Molecular Targeted Therapy; Multicenter Studies as Topic; Myelodysplastic Syndromes; Precision Medicine; Prognosis; Risk Assessment; Severity of Illness Index | 2020 |
Myelodysplastic syndromes: moving towards personalized management.
Topics: Anemia; Erythropoiesis; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2020 |
Novel therapies in low- and high-risk myelodysplastic syndrome.
Topics: Activin Receptors, Type II; Anemia; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Erythrocyte Transfusion; Hematinics; Humans; Immunoglobulin Fc Fragments; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Oligonucleotides; Prognosis; Recombinant Fusion Proteins; Risk Assessment; Stem Cell Transplantation; Sulfonamides; Thalidomide; Thrombopoietin; Transplantation, Homologous | 2019 |
How we treat lower-risk myelodysplastic syndromes.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Lenalidomide; Myelodysplastic Syndromes; Risk Factors; Thalidomide | 2013 |
Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.
Topics: Anemia; Anemia, Macrocytic; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2013 |
Does anything work for anaemia in myelofibrosis?
Topics: Androgens; Anemia; Blood Transfusion; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Interferons; Lenalidomide; Nitriles; Oxymetholone; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Thalidomide | 2014 |
[Supportive care in multiple myeloma for continuing anti-myeloma therapies].
Topics: Anemia; Bone Density Conservation Agents; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Diphosphonates; Humans; Hypercalcemia; Kidney Diseases; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2014 |
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunoglobulin M; Lenalidomide; Lymphatic Diseases; Neoplasm Recurrence, Local; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Splenomegaly; Thalidomide; Thrombocytopenia; Vincristine; Waldenstrom Macroglobulinemia | 2016 |
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Topics: Anemia; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 5; Disease Progression; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2017 |
Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
Topics: Aged; Anemia; Animals; Apoptosis; Blood Transfusion; Bone Marrow; cdc25 Phosphatases; Cell Nucleus; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Clone Cells; Combined Modality Therapy; Erythropoiesis; Forecasting; G2 Phase; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Rats; Receptors, Erythropoietin; Thalidomide | 2010 |
Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
Topics: Anemia; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Clone Cells; Combined Modality Therapy; Disease Progression; Erythropoiesis; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Risk; Survival Analysis; Thalidomide | 2010 |
Current and future management options for myelodysplastic syndromes.
Topics: Adenine Nucleotides; Anemia; Arabinonucleosides; Benzamides; Bone Marrow; Clofarabine; DNA Methylation; Drugs, Investigational; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Risk Factors; Thalidomide; Thrombopoietin | 2010 |
Multiple myeloma.
Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Management of the adverse effects of lenalidomide in multiple myeloma.
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Humans; Infections; Lenalidomide; Multiple Myeloma; Neutropenia; Practice Guidelines as Topic; Renal Insufficiency; Thalidomide; Thrombocytopenia; Treatment Outcome; Venous Thromboembolism | 2011 |
Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
Topics: Anemia; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Delivery Systems; Erythropoiesis; Erythropoietin; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Recombinant Proteins; Thalidomide; Treatment Outcome | 2006 |
Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes.
Topics: Algorithms; Anemia; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Delivery Systems; Humans; Lenalidomide; Medical Oncology; Myelodysplastic Syndromes; Practice Guidelines as Topic; Risk Factors; Thalidomide | 2006 |
[Pathophysiology, diagnosis and treatment of anemia].
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Thalidomide; Triazoles | 2008 |
[Development trend in new therapeutic approaches for anemia].
Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles | 2008 |
15 trial(s) available for lenalidomide and Anemia
| Article | Year |
|---|---|
Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Febrile Neutropenia; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Progression-Free Survival; Remission Induction; Treatment Outcome; Young Adult | 2020 |
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia | 2017 |
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; CTLA-4 Antigen; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Humans; Ipilimumab; Lenalidomide; Male; Middle Aged; Neoplasms; Outcome Assessment, Health Care; Young Adult | 2018 |
Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial.
Topics: Administration, Oral; Aged; Anemia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Hematinics; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Prednisone; Treatment Outcome | 2019 |
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anemia; Dexamethasone; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Dialysis; Survival Analysis; Thalidomide; Thrombocytopenia; Treatment Outcome | 2015 |
Lenalidomide is safe and active in Waldenström macroglobulinemia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Immunologic Factors; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome; Waldenstrom Macroglobulinemia | 2015 |
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
Topics: Aged; Anemia; Angiogenesis Inhibitors; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; Erythropoietin; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Prognosis; Prospective Studies; Risk Factors; Thalidomide | 2016 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Infections; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Remission Induction; Thalidomide; Treatment Outcome | 2017 |
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Immunoglobulin M; Lenalidomide; Male; Middle Aged; Neutropenia; Rituximab; Thalidomide; Thrombocytopenia; Waldenstrom Macroglobulinemia | 2009 |
Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Asian People; Chromosome Deletion; Chromosomes, Human, Pair 5; Chronic Disease; Female; Humans; Japan; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Thalidomide; Treatment Outcome | 2009 |
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; Glucocorticoids; Humans; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Neutropenia; Platelet-Derived Growth Factor; Prednisone; Primary Myelofibrosis; Thalidomide; Thrombocytopenia; Transforming Growth Factor beta; Treatment Outcome | 2009 |
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lenalidomide; Male; Middle Aged; Nausea; Neutropenia; Orchiectomy; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Thalidomide; Treatment Outcome; Vomiting | 2010 |
Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Retrospective Studies; Thalidomide; Thrombocytopenia; Treatment Outcome | 2010 |
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Hyperglycemia; Hypophosphatemia; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Topics: Administration, Oral; Adult; Aged; Anemia; Anemia, Myelophthisic; Female; Hemoglobins; Humans; Janus Kinase 2; Lenalidomide; Male; Neovascularization, Pathologic; Neutropenia; Platelet Count; Point Mutation; Primary Myelofibrosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Remission Induction; Sequence Deletion; Splenomegaly; Thalidomide; Thrombocytopenia; Time Factors | 2006 |
25 other study(ies) available for lenalidomide and Anemia
| Article | Year |
|---|---|
Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cohort Studies; Dexamethasone; Female; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Slovakia | 2022 |
Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche.
Topics: Anemia; Animals; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Macrophages; Mice; Myelodysplastic Syndromes; Thalidomide | 2022 |
Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis.
Topics: Aged; Anemia; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Primary Myelofibrosis; Retrospective Studies; Thalidomide | 2020 |
Therapy for lower-risk MDS.
Topics: Activin Receptors, Type II; Aged; Anemia; Blood Transfusion; Disease Management; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Fc Fragments; Lenalidomide; Male; Mutation; Myelodysplastic Syndromes; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2020 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
Topics: Aged; Aged, 80 and over; Anemia; Azacitidine; Databases, Factual; Decitabine; Electronic Health Records; Enzyme Inhibitors; Female; Hematinics; Humans; Immunologic Factors; Iron Chelating Agents; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Proportional Hazards Models; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; United States | 2018 |
Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report.
Topics: Aged; Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; B-Lymphocytes; Bone Marrow; Chromosome Deletion; Cyclophosphamide; Dexamethasone; Disease Progression; Enhancer of Zeste Homolog 2 Protein; Humans; Lenalidomide; Male; Mutation; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thrombocytopenia; Treatment Outcome | 2019 |
Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.
Topics: Aged; Aged, 80 and over; Anemia; Austria; Dose-Response Relationship, Drug; Female; Humans; Immunologic Factors; Lenalidomide; Leukopenia; Male; Middle Aged; Primary Myelofibrosis; Thalidomide; Thrombocytopenia; Treatment Outcome | 2013 |
Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
Topics: Acute Kidney Injury; Anemia; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Drug Monitoring; Drug Substitution; Flank Pain; Humans; Immunoglobulin kappa-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Renal Dialysis; Thalidomide | 2013 |
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Biomarkers, Tumor; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Survival Analysis; Thalidomide; Time Factors | 2014 |
Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach?
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Fatigue; Humans; Hypertension, Renal; Immunoglobulin Light Chains; Kidney; Kidney Failure, Chronic; Lenalidomide; Male; Myalgia; Paraproteinemias; Proteinuria; Remission Induction; Thalidomide | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide | 2014 |
Transiently Pink-Tinged Serum in a Patient With Multiple Myeloma and Anemia Undergoing Lenalidomide Treatment.
Topics: Anemia; Antineoplastic Agents; Female; Hemolysis; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2015 |
Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Bortezomib; Dexamethasone; Erythrocyte Indices; Erythroid Cells; Erythropoiesis; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Theoretical; Multiple Myeloma; Thalidomide; Treatment Outcome | 2016 |
Anaemia with inflammation responding to lenalidomide.
Topics: Aged; Anemia; Female; Humans; Immunologic Factors; Inflammation; Lenalidomide; Thalidomide; Treatment Outcome | 2016 |
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Analysis; Thalidomide; Treatment Outcome; Young Adult | 2017 |
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Topics: Anemia; Antineoplastic Agents; Azacitidine; Cost of Illness; Costs and Cost Analysis; Darbepoetin alfa; Decision Support Techniques; Deferoxamine; Drug Costs; Drug Therapy; Epoetin Alfa; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Recombinant Proteins; Siderophores; Thalidomide; United States | 2008 |
Management of myelodysplastic syndromes in the geriatric patient.
Topics: Aged; Anemia; Antineoplastic Agents; Azacitidine; Decitabine; Erythrocyte Transfusion; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2009 |
Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide.
Topics: Aged; Anemia; Antineoplastic Agents; Cell Survival; Drug Therapy, Combination; Female; Hematinics; Hemoglobins; Humans; Lenalidomide; Myelodysplastic Syndromes; Sequence Deletion; Thalidomide | 2010 |
Treatment considerations for primary myelofibrosis.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Neovascularization, Pathologic; Primary Myelofibrosis; Prognosis; Risk Factors; Thalidomide | 2010 |
Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
Topics: Aged; Anemia; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2012 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Muscle Weakness; Neutropenia; Pneumonia; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide (Revlimid) for anemia of myelodysplastic syndrome.
Topics: Anemia; Chromosome Deletion; Chromosomes, Human, Pair 5; Contraindications; Female; Humans; Lenalidomide; Myelodysplastic Syndromes; Pregnancy; Pregnancy Complications; Thalidomide; Transfusion Reaction | 2006 |
Lenalidomide: from bench to bedside (part 1).
Topics: Anemia; Antineoplastic Agents; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2006 |
Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes.
Topics: Anemia; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Medical Oncology; Myelodysplastic Syndromes; Thalidomide | 2006 |